NASDAQ: KROS
Keros Therapeutics, Inc.
Healthcare · Biotechnology
After hours: $11.03(0%) · as of 4:10 PM ET
Market Cap
$352.94M
52w High
$22.55
52w Low
$9.69
P/E
4.80
Volume
153.22K
Outstanding Shares
32.00M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 27.29% over the last year. Revenue declined 93.55% over the trailing twelve months. Operating margin moved from 0.13% to -675.82%. Free cash flow declined 191.35% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/S, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -675.82%. Revenue declined 93.55% — this read reverses if that trend stabilizes. Free cash flow fell 191.35% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
10
Buy
7
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q4 FY26 · EPS est -$0.89 · Revenue est $15.42M
View